Interestingly, these effects of CsA and FK506 were not seen in NFATc1 knock-down cell lines, suggesting that these non-selective NFAT inhibitors suppress bladder cancer growth predominantly through the NFATc1 pathway. Here, NFATC1 is linked to urinary bladder carcinoma.